Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Aquestive Therapeutics, Inc.NASDAQ: AQST
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.07, compared with -$0.24 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.61.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$0.47 (+38.3%) for the fiscal year ending Dec 2026, a step up from the -49.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.07+73.1% QoQ
- Last fiscal yearDec 2025
- -$0.76-49.0% YoY
- LTMMar 2026
- -$0.61-3.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +70.8% | +25.0% | -45.8 pp |
| 1 year | -49.0% | +38.3% | +87.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.76) USD
- Year-over-year change
- -49.0%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.76) | -49.0% |
| FY2024 | 2024-12-31 | (0.51) | -292.3% |
| FY2023 | 2023-12-31 | (0.13) | +88.4% |
| FY2022 | 2022-12-31 | (1.12) | +39.5% |
| FY2021 | 2021-12-31 | (1.85) | — |
EPS (Diluted) vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 EPS (Diluted) of -$0.61 is the 8th highest of the 10 companies compared; the peer median is -$0.02.
- Its year-over-year change of -3.4% is the 5th highest of 10, against a peer median of -39.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.15 | +213.3% | — | |
| LTM Mar 2026 | $2.04 | +68.1% | — | |
| LTM Mar 2026 | $1.66 | -39.9% | +5.3% | |
| LTM Mar 2026 | $0.07 | +121.3% | — | |
| LTM Sep 2026 | -$0.02 | -100.8% | — | |
| LTM Mar 2026 | -$0.38 | +6.3% | — | |
| LTM Mar 2026 | -$0.49 | -97.8% | — | |
| LTM Mar 2026 | -$0.61 | -3.4% | — | |
| LTM Jun 2026 | -$1.92 | -267.1% | — | |
| LTM Mar 2026 | -$4.05 | -437.5% | — | |
| Peer median (excluding AQST) | -$0.02 | -39.9% | +5.3% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | 14.99M | 19.39M | 20.83M | 17.87M | 17.15M |
| Gross Profit | 35.84M | 28.29M | 29.75M | 39.69M | 27.39M |
| Gross Margin | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| Research & Development | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| Selling, General & Admin | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Operating Expenses | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 559K |
| EBITDA | (45.11M) | (39.58M) | 1.18M | (26.62M) | (66.13M) |
| EBITDA Margin | -88.8% | -83.0% | 2.3% | -46.2% | -148.4% |
| Operating Income | (34.68M) | (42.07M) | (15.1M) | (30.77M) | (69.65M) |
| Operating Margin | -68.2% | -88.2% | -29.9% | -53.5% | -156.4% |
| Interest Income | 423K | 99K | 16.32M | 3.44M | 0 |
| Interest Expense | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income / Expenses | (35.86M) | (12.34M) | 7.48M | (13.38M) | (14.13M) |
| Income Before Tax | (70.54M) | (54.41M) | (7.63M) | (44.15M) | (83.78M) |
| Pre-Tax Margin | -138.8% | -114.1% | -15.1% | -76.7% | -188.1% |
| Income Tax Expense | 0 | 0 | 245K | (14K) | 0 |
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Net Margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (Basic) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| EPS (Diluted) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| Weighted Avg Shares | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Weighted Avg Shares (Diluted) | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.